SCHEMBL1894380

SCHEMBL1894380

NCC(=O)N1C(=O)c2cccc3c(N4CCOCC4)ccc(c23)C1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 15/20 0.62
KMT2A Q03164 15/20 0.62
LMNA P02545 5/20 0.62
HDAC6 Q9UBN7 3/20 0.59
HDAC3 O15379 3/20 0.59
HDAC1 Q13547 3/20 0.59
HDAC2 Q92769 2/20 0.59
HDAC8 Q9BY41 2/20 0.59
HDAC11 Q96DB2 2/20 0.59
NCOR2 Q9Y618 2/20 0.59
HDAC10 Q969S8 1/20 0.55
L3MBTL1 Q9Y468 8/20 0.54
MAPT P10636 6/20 0.54
MAPK1 P28482 5/20 0.54
HTT P42858 5/20 0.54
CRHBP P24387 4/20 0.54
CRHR2 Q13324 4/20 0.54
POLB P06746 2/20 0.54
THRB P10828 1/20 0.54
SMN1; SMN2 Q16637 6/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7712239 0.81 MEN1 (0.72) MEN1KMT2ALMNAHDAC6HDAC3
SCHEMBL28197565 0.81 HDAC6 (0.64) MEN1KMT2ALMNAHDAC6HDAC3
SCHEMBL12660521 0.80 MEN1 (0.64) MEN1KMT2ALMNAHDAC6HDAC3
SCHEMBL28198225 0.79 HDAC6 (0.71) MEN1KMT2ALMNAHDAC6HDAC3
SCHEMBL16784368 0.79 MEN1 (0.68) MEN1KMT2ALMNAHDAC6HDAC3
SCHEMBL22699960 0.79 MEN1 (0.80) MEN1KMT2ALMNAHDAC6HDAC3
SCHEMBL28203805 0.78 HDAC6 (0.70) MEN1KMT2ALMNAHDAC6HDAC3
SCHEMBL18648444 0.78 MEN1 (0.64) MEN1KMT2ALMNAHDAC6HDAC3
SCHEMBL12696859 0.77 HDAC3 (0.80) MEN1KMT2ALMNAHDAC6HDAC3
SCHEMBL12660535 0.77 HDAC3 (0.65) MEN1KMT2ALMNAHDAC6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947839-B2 Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use GENENTECH, INC. (US) 2011-05-24 US disclosed
EP-1817059-A2 CONJUGATES OF 1,8-BIS-NAPHTHALIMIDES WITH AN ANTIBODY Genentech, Inc. (US) 2007-08-15 EP disclosed
WO-2007064345-A9 HETEROCYCLIC-SUBSTITUTED BIS-1,8 NAPHTHALIMIDE COMPOUNDS, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE GENENTECH INC (US) 2007-07-12 WO disclosed
US-20070134243-A1 Antibody drug conjugates and methods GENENTECH, INC. 2007-06-14 US disclosed
US-20060182751-A1 Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use GENENTECH, INC. (US) 2006-08-17 US disclosed
WO-2006060533-A2 CONJUGATES OF 1, 8-BIS-NAPHTHALIMIDES WITH AN ANTIBODY GENENTECH, INC. (US) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060182751-A1 Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use CCNY, CCNI, MKI67 MEN1 1399/4885KMT2A 707/4885LMNA 426/4885
US-20070134243-A1 Antibody drug conjugates and methods BOD1L1, MKI67, CCNI MEN1 1674/4885KMT2A 1301/4885LMNA 774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.